Ciprofloxacin Potentiates Ferroptosis via Mitochondrial Zinc Pathway

Study Background and Research Question

Ferroptosis is a regulated form of cell death defined by iron-dependent lipid peroxidation, distinct from classical apoptosis, necroptosis, or pyroptosis. Its manipulation holds promise for improving the selectivity and efficacy of cancer therapies, but the context-specific regulation of ferroptosis remains incompletely characterized (source: internal_review). Ciprofloxacin (CFX), a widely prescribed fluoroquinolone antibiotic, is known for its antimicrobial action through inhibition of bacterial DNA gyrase and topoisomerase, but has also been reported to exert anti-tumor effects in various settings. Prior work established that CFX could suppress erastin-induced ferroptosis via stabilization of glutathione peroxidase 4 (GPX4), thereby supporting cancer cell survival. However, the effects of CFX on ferroptosis triggered by other molecular inducers, particularly RSL3 (a GPX4 inhibitor), remained unclear. This study sought to address whether CFX modulates RSL3-induced ferroptosis and to elucidate the underlying molecular mechanisms (source: internal_review).

Key Innovation from the Reference Study

The central innovation of this research lies in the discovery that CFX, contrary to its protective role in erastin-induced ferroptosis, synergistically enhances RSL3-induced ferroptosis in cancer cells. Mechanistically, this potentiation is mediated by the promotion of mitochondrial Zn²⁺ accumulation, which depends on the activation of the STING1–CAV2 pathway. This work thus reveals a dual, stimulus-dependent function of CFX in ferroptosis regulation, highlighting the complexity of antibiotic-modulated cell death pathways (source: internal_review; source: reference_paper).

Methods and Experimental Design Insights

The authors employed a combination of antibiotic screening, cell viability and cytotoxicity assays, molecular genetics, and metal ion imaging to dissect the role of CFX in ferroptosis. Cancer cell lines were treated with CFX at low and moderate concentrations, alone and in combination with RSL3. Cell viability measurement was performed using ATP-based luminescent assays and complementary staining approaches, enabling quantitative assessment of cell death in response to the treatments (source: product_spec). Further, zinc accumulation was visualized using Zn²⁺-sensitive fluorescent probes, while mitochondrial reactive oxygen species (ROS) production and DNA stress were evaluated through established biochemical and imaging protocols. Genetic knockdown and pharmacological inhibition approaches were used to interrogate the requirement of the STING1–CAV2 signaling axis and mitochondrial Zn²⁺ transporters in the observed effects.

Protocol Parameters

• assay | ATP luminescent assay | 10–30,000 cells per well | applicable for high-sensitivity viability quantification in ferroptosis and cytotoxicity assays | enables detection of subtle metabolic changes in low-density cancer cell samples | product_spec
• assay | RSL3 (ferroptosis inducer) | 1–2 μM | appropriate for inducing GPX4-dependent ferroptosis in a variety of tumor cell lines | well-documented dosage for robust ferroptosis induction | reference_paper
• assay | Ciprofloxacin | 1–10 μM | used to probe modulatory effects on cell death pathways, including ferroptosis | matches clinically relevant and experimental concentrations | reference_paper
• assay | Zn²⁺ detection probe | 0.5–1 μM | enables real-time visualization of mitochondrial zinc accumulation | critical for linking Zn²⁺ dysregulation to ferroptotic cell death | reference_paper
• assay | Cell viability measurement time | 10–60 min post-treatment | supports rapid and dynamic monitoring of cell death kinetics | aligns with luminescent ATP cell viability assay protocols | workflow_recommendation

Core Findings and Why They Matter

The study found that CFX significantly sensitizes cancer cells to RSL3-induced ferroptosis, in contrast to its inhibitory effect on erastin-induced ferroptosis. This potentiation is accompanied by pronounced mitochondrial DNA stress, robust activation of the STING1–CAV2 pathway, and marked accumulation of Zn²⁺ within mitochondria. The solute carrier SLC25A25 was identified as a key transporter mediating Zn²⁺ influx into mitochondria upon CFX and RSL3 co-treatment. Elevated mitochondrial Zn²⁺ triggered increased ROS generation, amplifying ferroptotic cell death. Importantly, genetic or pharmacological disruption of STING1, CAV2, or SLC25A25 abrogated these effects, confirming the pathway's critical role (source: reference_paper). These findings underscore the context-dependent, dual nature of CFX in ferroptosis regulation. While CFX can protect against some forms of ferroptosis, it can also act as a potent sensitizer under specific stimuli, such as RSL3, by disrupting zinc homeostasis and promoting mitochondrial dysfunction. This duality has significant implications: it suggests that the therapeutic use of CFX or related antibiotics in oncology could be tailored to exploit ferroptosis for selective cancer cell elimination, depending on the molecular context (source: internal_review).

Comparison with Existing Internal Articles

Recent internal resources reinforce the centrality of robust cell viability and metabolism assays in dissecting ferroptosis mechanisms. For example, "Luminescent ATP Cell Viability Assay Kit I: Precision for Ferroptosis Research" highlights the importance of high-sensitivity luminescent ATP cell viability assays for quantifying subtle metabolic changes during ferroptosis, such as those observed with CFX and RSL3 co-treatment. Similarly, "Ciprofloxacin Enhances Ferroptosis via Mitochondrial Zinc Pathway" provides a concise review of the mechanistic link between antibiotic-induced zinc dysregulation and ferroptosis, echoing the novel findings of the present study. These resources converge on the value of luciferase luminescence detection in capturing rapid, early viability changes—critical for studies where cell death dynamics can shift within minutes. Such assay platforms have been validated for both cytotoxicity and apoptosis assays, offering streamlined workflows for ferroptosis research (source: internal_review).

Limitations and Transferability

Despite providing compelling evidence for a CFX–RSL3 synergy in ferroptosis via mitochondrial zinc accumulation, the study's findings are predominantly based on in vitro cancer cell models. The precise relevance of this pathway in vivo, especially in the context of mixed cell populations and systemic zinc homeostasis, remains to be determined. Furthermore, the dual role of CFX—protective in one ferroptotic context and sensitizing in another—highlights the necessity for careful consideration of drug timing, dosage, and cellular background in translational applications (source: reference_paper). Transferability of these findings to other cancer types, or to non-cancerous tissues, awaits further validation. The potential for off-target effects or unintended modulation of zinc-dependent processes also warrants close scrutiny in preclinical and clinical settings.

Research Support Resources

For researchers aiming to replicate or extend these ferroptosis studies, robust and sensitive cell viability measurement is essential. The Luminescent ATP Cell Viability Assay Kit I (SKU: K2041) offers a validated, ready-to-use solution based on luciferase luminescence detection, supporting rapid and precise quantification of metabolically active cells in ferroptosis, cytotoxicity, and cell metabolism assays (source: product_spec). This kit simplifies experimental workflows and ensures reproducibility when tracking cell fate in response to agents like CFX and RSL3. As always, optimal assay choice and parameter tuning should be guided by specific research questions and cell model requirements (workflow_recommendation).